Bioorganic and Medicinal Chemistry Letters (2019)
Update date:2022-08-04
Topics:
Trzoss, Michael
Covel, Jonathan A.
Kapoor, Mili
Moloney, Molly K.
Soltow, Quinlyn A.
Webb, Peter J.
Shaw, Karen Joy
Fosmanogepix (APX001) is a first-in-class prodrug molecule that is currently in Phase 2 clinical trials for invasive fungal infections. The active moiety manogepix (APX001A) inhibits the novel fungal protein Gwt1. Gwt1 catalyzes an early step in the GPI anchor biosynthesis pathway. Here we describe the synthesis and evaluation of 292 new and 24 previously described analogs that were synthesized using a series of advanced intermediates to allow for rapid analoging. Several compounds demonstrated significantly (8- to 32-fold) improved antifungal activity against both Cryptococcus neoformans and C. gattii as compared to manogepix. Further in vitro characterization identified three analogs with a similar preliminary safety and in vitro profile to manogepix and superior activity against Cryptococcus spp.
View MoreHangzhou GreenCo Science & Technology Co., Ltd.
Contact:86-571-88257303
Address:1713 Room,Jingui Building,Gudun Road,Xihu District,Hangzhou,China
Contact:+86-20-62802632;62802633
Address:Room 330 GIGCAS Building,No.511 Kehua Street,Tianhe District
xi'an taima biological engineering co., ltd.
Contact:+8615619038117
Address:6 No,keji road xi'an city of china
Shenzhen HwaGen Pharmaceutical Co., Ltd
website:http://www.rafflespt.com
Contact:+86-752-5538396
Address:Guangdong Huizhou China
Lonzeal Pharmaceuticals Co., Ltd.
website:http://www.lonzeal.com
Contact:+86-13381011962
Address:RM 801, Yue MOMA, No. 26 Anningzhuang Rd. Haidian District, Beijing, China
Doi:10.1055/s-0036-1588422
(2017)Doi:10.1021/jo01050a549
(1962)Doi:10.1002/chem.200903158
(2010)Doi:10.1016/j.tet.2008.11.103
(2009)Doi:10.1021/acs.orglett.0c04114
(2021)Doi:10.1016/j.bmcl.2007.01.065
(2007)